Clinical Trials Browser

Phase 2/3 × Recruiting × Topotecan × Clear all

NCT06161025 2026-05-22

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2/3 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04681417 2025-11-28

RETINO 2018

Phase 2/3 Recruiting

Other solid neoplasm

Retinoblastoma